News - Verséa
 
HomeCategory

News

Verséa™ Ophthalmics is Launching Novel, Point-of-Care, Tear-Based Diagnostic Test Platform at the AAO 2022

New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders   At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating...

Verséa Searching For Brightest Students and Recent Graduates at the University of Tampa to Join Paid Internship Program

Verséa is looking for this year’s brightest students and recent graduates to join our Paid Internship Program! Today we are at the University of Tampa searching for ambitious individuals who wish to gain professional experience in Marketing & Business Development at one of the fastest-growing healthcare companies in the U.S. CONTACT US TODAY at 1.813.345.2185...

Verséa™ Ophthalmics Signs Exclusive Global Commercialization Agreement With AXIM® Biotechnologies for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”   Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...

Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. announced as a Tampa Bay Business Journal 40 under 40 honoree

Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. (“Verséa”) has been announced as a Tampa Bay Business Journal 40 under 40 honoree. This is the most competitive award given by the Tampa Bay Business Journal, with over 500 nominations this year alone. The award recognizes exceptional business professionals, leaders and innovators under the...

Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President  to lead the company’s expansion into the ophthalmic market

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...

Successful first validation test on VCX™ Discovery Platform at UCSD Biomedical Lab

Verséa Discovery successfully ran its first validation test assays at the UCSD Biomedical Lab using its proprietary VCX™ Discovery Platform   The cellular based platform VCX™ Discovery Platform follows a proprietary process developed by Verséa Discovery. Through machine learning, the system links highly specific cellular functions (focused on mitochondrial biology and second messenger signaling) to...

Cannabinol (CBN) shows unique therapeutic potential in glaucoma

A recently published peer-reviewed scientific article “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma” has provided insight into unique therapeutic potential of Cannabinol (CBN) for glaucoma treatment   The article, published in a leading international journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease) (LINK to the article)...